Luteolin reverses MDR in osteosarcoma cells and may be a promising therapeutic agent for chemoresistant osteosarcoma by inhibiting the PTN/β-catenin/MDR1 signaling axis through miR-384 upregulation [140]. Here, PTN is linked to osteosarcoma.